Charles Schwab Investment Management Inc. Has $537,000 Stock Position in LifeMD, Inc. (NASDAQ:LFMD)

Charles Schwab Investment Management Inc. increased its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 5.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 108,478 shares of the company’s stock after purchasing an additional 6,034 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.25% of LifeMD worth $537,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp raised its position in LifeMD by 20.0% in the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after buying an additional 192,861 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of LifeMD by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock worth $4,293,000 after acquiring an additional 83,598 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of LifeMD by 496.4% in the third quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company’s stock valued at $462,000 after purchasing an additional 73,389 shares during the last quarter. Mirador Capital Partners LP lifted its position in shares of LifeMD by 139.3% in the fourth quarter. Mirador Capital Partners LP now owns 106,059 shares of the company’s stock worth $525,000 after purchasing an additional 61,731 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in LifeMD by 306.8% during the third quarter. XTX Topco Ltd now owns 55,738 shares of the company’s stock worth $292,000 after purchasing an additional 42,037 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LFMD has been the topic of several analyst reports. KeyCorp cut their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Mizuho began coverage on LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target for the company. HC Wainwright upped their price objective on LifeMD from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a report on Tuesday, March 11th. Finally, B. Riley upgraded shares of LifeMD to a “strong-buy” rating in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $11.43.

LifeMD Price Performance

LFMD stock opened at $5.44 on Tuesday. LifeMD, Inc. has a one year low of $3.99 and a one year high of $12.88. The stock has a market cap of $242.54 million, a price-to-earnings ratio of -8.50 and a beta of 1.50. The company has a fifty day moving average price of $5.84 and a two-hundred day moving average price of $5.44.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. Research analysts anticipate that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Jessica Friedeman sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares of the company’s stock, valued at approximately $962,200. This trade represents a 15.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Justin Schreiber sold 50,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the sale, the chief executive officer now directly owns 2,653,715 shares in the company, valued at $20,035,548.25. This represents a 1.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,000 shares of company stock worth $677,050 in the last 90 days. Company insiders own 15.97% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.